Free tool
FAERS Monitor: Vectical
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022087 or its brand name (Vectical, Calcitriol). Reports on generic versions are filed under their own applications.
Reports
20,497
Serious
15,764
77% of reports
Hospitalization
8,660
Death reported
2,698
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- nausea1,485
- diarrhoea1,212
- off label use1,165
- chronic kidney disease1,117
- vomiting1,112
- dyspnoea1,105
- fatigue1,063
- renal failure1,059
- acute kidney injury975
- death910
- drug hypersensitivity883
- drug ineffective831
- abdominal pain791
- headache784
- asthenia769
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 179 |
| 2005 | 245 |
| 2006 | 171 |
| 2007 | 190 |
| 2008 | 282 |
| 2009 | 390 |
| 2010 | 395 |
| 2011 | 413 |
| 2012 | 543 |
| 2013 | 567 |
| 2014 | 561 |
| 2015 | 896 |
| 2016 | 1,195 |
| 2017 | 1,385 |
| 2018 | 1,742 |
| 2019 | 2,334 |
| 2020 | 1,555 |
| 2021 | 1,454 |
| 2022 | 1,160 |
| 2023 | 1,215 |
| 2024 | 1,421 |
| 2025 | 1,212 |
| 2026 | 992 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,033,662 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| chronic kidney diseaseSignal | 1,117 | 15.3 | 14.4 | 14,744 |
| renal failureSignal | 1,059 | 8.2 | 7.8 | 6,719 |
| acute kidney injurySignal | 975 | 6.6 | 6.2 | 4,606 |
| drug hypersensitivitySignal | 883 | 4.7 | 4.4 | 2,579 |
| abdominal painSignal | 791 | 3.5 | 3.3 | 1,419 |
| vomitingSignal | 1,112 | 2.4 | 2.3 | 954 |
| astheniaSignal | 769 | 2.1 | 2.0 | 450 |
| dyspnoeaSignal | 1,105 | 2.0 | 1.9 | 570 |
| diarrhoea | 1,212 | 1.9 | 1.8 | 557 |
| nausea | 1,485 | 1.9 | 1.8 | 686 |
| fatigue | 1,063 | 1.4 | 1.3 | 126 |
| off label use | 1,165 | 1.4 | 1.3 | 119 |
| headache | 784 | 1.3 | 1.2 | 50 |
| death | 910 | 1.1 | 1.0 | 6 |
| drug ineffective | 831 | 0.6 | 0.6 | 171 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.